INS and Hypoglycemia: Regression trials (depicted in Figure 5A) were initiated at 13 weeks, when the mice already had appreciable tumor burden, and continued to a defined endpoint 2 weeks later (15 weeks), when most untreated animals have succumbed to hypoglycemia attributable to increased insulin secretion from the multiple pancreatic tumors that develop.